A TRAMP‐derived orthotopic prostate syngeneic (TOPS) cancer model for investigating anti‐tumor treatments

A TRAMP‐derived orthotopic prostate syngeneic (TOPS) cancer model for investigating... INTRODUCTIONProstate cancer is the most common non‐cutaneous malignancy and the second leading cause of cancer‐related death in North American men. Patients diagnosed with localized disease are usually treated with surgery or radiotherapy; however, many of these patients are not cured and may later develop a more advanced recurrent form of the disease. Patients with advanced prostate cancer are primarily treated with hormone ablation therapy. While initially most of these patients respond well to treatment, over time the tumor becomes unresponsive and develops into castration‐resistant prostate cancer (CRPC). Current therapies for patients with CRPC, which include taxol‐based chemotherapy, have only temporary effectiveness. Therefore, other treatments that are more effective against advanced prostate cancer and CRPC are needed.Mouse models are essential for expanding our understanding of prostate cancer initiation, development, and progression. In addition, they are vital for the pre‐clincial development of new treatments for advanced prostate cancer. Current mouse models for prostate cancer consist of genetically engineered transgenic mice and mice bearing xenograft tumors. In genetically engineered mice, many genes that are implicated in cancer initiation, development, and progression are altered and modified to create mouse models that mimic cancer progression observed in humans. The advantage of using transgenic mouse http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png The Prostate Wiley

A TRAMP‐derived orthotopic prostate syngeneic (TOPS) cancer model for investigating anti‐tumor treatments

Loading next page...
 
/lp/wiley/a-tramp-derived-orthotopic-prostate-syngeneic-tops-cancer-model-for-UTCkHI0tt4
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
© 2018 Wiley Periodicals, Inc.
ISSN
0270-4137
eISSN
1097-0045
D.O.I.
10.1002/pros.23490
Publisher site
See Article on Publisher Site

Abstract

INTRODUCTIONProstate cancer is the most common non‐cutaneous malignancy and the second leading cause of cancer‐related death in North American men. Patients diagnosed with localized disease are usually treated with surgery or radiotherapy; however, many of these patients are not cured and may later develop a more advanced recurrent form of the disease. Patients with advanced prostate cancer are primarily treated with hormone ablation therapy. While initially most of these patients respond well to treatment, over time the tumor becomes unresponsive and develops into castration‐resistant prostate cancer (CRPC). Current therapies for patients with CRPC, which include taxol‐based chemotherapy, have only temporary effectiveness. Therefore, other treatments that are more effective against advanced prostate cancer and CRPC are needed.Mouse models are essential for expanding our understanding of prostate cancer initiation, development, and progression. In addition, they are vital for the pre‐clincial development of new treatments for advanced prostate cancer. Current mouse models for prostate cancer consist of genetically engineered transgenic mice and mice bearing xenograft tumors. In genetically engineered mice, many genes that are implicated in cancer initiation, development, and progression are altered and modified to create mouse models that mimic cancer progression observed in humans. The advantage of using transgenic mouse

Journal

The ProstateWiley

Published: Jan 1, 2018

Keywords: ; ; ;

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial